223 related articles for article (PubMed ID: 18411416)
1. NOTCH1 extracellular juxtamembrane expansion mutations in T-ALL.
Sulis ML; Williams O; Palomero T; Tosello V; Pallikuppam S; Real PJ; Barnes K; Zuurbier L; Meijerink JP; Ferrando AA
Blood; 2008 Aug; 112(3):733-40. PubMed ID: 18411416
[TBL] [Abstract][Full Text] [Related]
2. Leukemia-associated mutations within the NOTCH1 heterodimerization domain fall into at least two distinct mechanistic classes.
Malecki MJ; Sanchez-Irizarry C; Mitchell JL; Histen G; Xu ML; Aster JC; Blacklow SC
Mol Cell Biol; 2006 Jun; 26(12):4642-51. PubMed ID: 16738328
[TBL] [Abstract][Full Text] [Related]
3. Redundancy and specificity of the metalloprotease system mediating oncogenic NOTCH1 activation in T-ALL.
Sulis ML; Saftig P; Ferrando AA
Leukemia; 2011 Oct; 25(10):1564-9. PubMed ID: 21625236
[TBL] [Abstract][Full Text] [Related]
4. New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia.
Hales EC; Taub JW; Matherly LH
Cell Signal; 2014 Jan; 26(1):149-61. PubMed ID: 24140475
[TBL] [Abstract][Full Text] [Related]
5. Notch signaling contributes to proliferation and tumor formation of human T-cell leukemia virus type 1-associated adult T-cell leukemia.
Pancewicz J; Taylor JM; Datta A; Baydoun HH; Waldmann TA; Hermine O; Nicot C
Proc Natl Acad Sci U S A; 2010 Sep; 107(38):16619-24. PubMed ID: 20823234
[TBL] [Abstract][Full Text] [Related]
6. CUTLL1, a novel human T-cell lymphoma cell line with t(7;9) rearrangement, aberrant NOTCH1 activation and high sensitivity to gamma-secretase inhibitors.
Palomero T; Barnes KC; Real PJ; Glade Bender JL; Sulis ML; Murty VV; Colovai AI; Balbin M; Ferrando AA
Leukemia; 2006 Jul; 20(7):1279-87. PubMed ID: 16688224
[TBL] [Abstract][Full Text] [Related]
7. Characterization of Notch1 antibodies that inhibit signaling of both normal and mutated Notch1 receptors.
Aste-Amézaga M; Zhang N; Lineberger JE; Arnold BA; Toner TJ; Gu M; Huang L; Vitelli S; Vo KT; Haytko P; Zhao JZ; Baleydier F; L'Heureux S; Wang H; Gordon WR; Thoryk E; Andrawes MB; Tiyanont K; Stegmaier K; Roti G; Ross KN; Franlin LL; Wang H; Wang F; Chastain M; Bett AJ; Audoly LP; Aster JC; Blacklow SC; Huber HE
PLoS One; 2010 Feb; 5(2):e9094. PubMed ID: 20161710
[TBL] [Abstract][Full Text] [Related]
8. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia.
Weng AP; Ferrando AA; Lee W; Morris JP; Silverman LB; Sanchez-Irizarry C; Blacklow SC; Look AT; Aster JC
Science; 2004 Oct; 306(5694):269-71. PubMed ID: 15472075
[TBL] [Abstract][Full Text] [Related]
9. An activating intragenic deletion in NOTCH1 in human T-ALL.
Haydu JE; De Keersmaecker K; Duff MK; Paietta E; Racevskis J; Wiernik PH; Rowe JM; Ferrando A
Blood; 2012 May; 119(22):5211-4. PubMed ID: 22510873
[TBL] [Abstract][Full Text] [Related]
10. T cell acute lymphoblastic leukemia/lymphoma: a human cancer commonly associated with aberrant NOTCH1 signaling.
Pear WS; Aster JC
Curr Opin Hematol; 2004 Nov; 11(6):426-33. PubMed ID: 15548998
[TBL] [Abstract][Full Text] [Related]
11. In vitro validation of gamma-secretase inhibitors alone or in combination with other anti-cancer drugs for the treatment of T-cell acute lymphoblastic leukemia.
De Keersmaecker K; Lahortiga I; Mentens N; Folens C; Van Neste L; Bekaert S; Vandenberghe P; Odero MD; Marynen P; Cools J
Haematologica; 2008 Apr; 93(4):533-42. PubMed ID: 18322257
[TBL] [Abstract][Full Text] [Related]
12. Activating Notch1 mutations in mouse models of T-ALL.
O'Neil J; Calvo J; McKenna K; Krishnamoorthy V; Aster JC; Bassing CH; Alt FW; Kelliher M; Look AT
Blood; 2006 Jan; 107(2):781-5. PubMed ID: 16166587
[TBL] [Abstract][Full Text] [Related]
13. The tumor suppressor gene hCDC4 is frequently mutated in human T-cell acute lymphoblastic leukemia with functional consequences for Notch signaling.
Malyukova A; Dohda T; von der Lehr N; Akhoondi S; Corcoran M; Heyman M; Spruck C; Grandér D; Lendahl U; Sangfelt O
Cancer Res; 2007 Jun; 67(12):5611-6. PubMed ID: 17575125
[TBL] [Abstract][Full Text] [Related]
14. Structure of the Notch1-negative regulatory region: implications for normal activation and pathogenic signaling in T-ALL.
Gordon WR; Roy M; Vardar-Ulu D; Garfinkel M; Mansour MR; Aster JC; Blacklow SC
Blood; 2009 Apr; 113(18):4381-90. PubMed ID: 19075186
[TBL] [Abstract][Full Text] [Related]
15. NOTCH1 mutations in T-cell acute lymphoblastic leukemia: prognostic significance and implication in multifactorial leukemogenesis.
Zhu YM; Zhao WL; Fu JF; Shi JY; Pan Q; Hu J; Gao XD; Chen B; Li JM; Xiong SM; Gu LJ; Tang JY; Liang H; Jiang H; Xue YQ; Shen ZX; Chen Z; Chen SJ
Clin Cancer Res; 2006 May; 12(10):3043-9. PubMed ID: 16707600
[TBL] [Abstract][Full Text] [Related]
16. Effects of S1 cleavage on the structure, surface export, and signaling activity of human Notch1 and Notch2.
Gordon WR; Vardar-Ulu D; L'Heureux S; Ashworth T; Malecki MJ; Sanchez-Irizarry C; McArthur DG; Histen G; Mitchell JL; Aster JC; Blacklow SC
PLoS One; 2009 Aug; 4(8):e6613. PubMed ID: 19701457
[TBL] [Abstract][Full Text] [Related]
17. Gamma-secretase inhibitor does not induce cytotoxicity in adult T-cell leukemia cell lines despite NOTCH1 expression.
Suzuki S; Hourai S; Uozumi K; Uchida Y; Yoshimitsu M; Miho H; Arima N; Ueno SI; Ishitsuka K
BMC Cancer; 2022 Oct; 22(1):1065. PubMed ID: 36243685
[TBL] [Abstract][Full Text] [Related]
18. NOTCH1/FBXW7 mutation identifies a large subgroup with favorable outcome in adult T-cell acute lymphoblastic leukemia (T-ALL): a Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL) study.
Asnafi V; Buzyn A; Le Noir S; Baleydier F; Simon A; Beldjord K; Reman O; Witz F; Fagot T; Tavernier E; Turlure P; Leguay T; Huguet F; Vernant JP; Daniel F; Béné MC; Ifrah N; Thomas X; Dombret H; Macintyre E
Blood; 2009 Apr; 113(17):3918-24. PubMed ID: 19109228
[TBL] [Abstract][Full Text] [Related]
19. Deletion-based mechanisms of Notch1 activation in T-ALL: key roles for RAG recombinase and a conserved internal translational start site in Notch1.
Ashworth TD; Pear WS; Chiang MY; Blacklow SC; Mastio J; Xu L; Kelliher M; Kastner P; Chan S; Aster JC
Blood; 2010 Dec; 116(25):5455-64. PubMed ID: 20852131
[TBL] [Abstract][Full Text] [Related]
20. Oncogenic NOTCH1 control of MYC and PI3K: challenges and opportunities for anti-NOTCH1 therapy in T-cell acute lymphoblastic leukemias and lymphomas.
Palomero T; Ferrando A
Clin Cancer Res; 2008 Sep; 14(17):5314-7. PubMed ID: 18765521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
